ReviewFrontiers in ophthalmology2023
Glaucoma and microglia-induced neuroinflammation.
Review in Frontiers in ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Metabolic and Immunometabolic Neuroprotection in Glaucoma: Mitochondrial Dysfunction, Neuroinflammation, and Emerging Therapeutic Strategies.Molecules (Basel, Switzerland) · 2026Review
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Dual role of microglia in glaucoma: Regulation of neuroinflammation and neuroregeneration.Neural regeneration research · 2026Article
- Targeting Neuroinflammation and Oxidative Stress to Slow Neurodegeneration in the Visual System.Journal of clinical medicine · 2026Review
- Review
- Ocular and Systemic Pharmacokinetics of Baicalein and Baicalin After Intravitreal Injection and Oral Administration in Mice.Pharmaceutics · 2026Article
- Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Sleep Deficit and Inflammatory Markers as Combined Risk Factors for Glaucoma Progression: A Prospective Longitudinal Observational Cohort Study.International journal of molecular sciences · 2026Observational
- Stage- and compartment-specific remodeling of autophagy and selective mitophagy in glaucoma: from aqueous outflow dysfunction to retinal ganglion cell neurodegeneration.Frontiers in cell and developmental biology · 2026Review
- Mapping Multiscale Brain Changes in Primary Angle-Closure Glaucoma Using Regional Radiomics Similarity Networks.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.American journal of translational research · 2026Article
- TSPO in systemic-ocular immunometabolic crosstalk: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Hyaluronic Acid-PEG-PLGA Nanoparticles Encapsulating Myricetin Attenuate NMDA-Induced Retinal Ganglion Cell Injury Associated with Microglia-Related Neuroinflammatory Responses.International journal of nanomedicine · 2026Article
- Enzymatic glycosylation as a potential molecular link between Alzheimer's disease and glaucoma.International journal of ophthalmology · 2026Review
- OPTN protects retinal ganglion cells and ameliorates neuroinflammation in optic neuropathies.Communications biology · 2025Article
- Spatiotemporal Immune Dynamics in Experimental Retinal Ganglion Cell Injury Models.Immunity, inflammation and disease · 2025Review
- Developing and validating an explainable clinlabomics-based machine-learning model for screening primary angle-closure glaucoma in the context of PPPM.The EPMA journal · 2025Article
- MicroRNA-21-5p from induced pluripotent stem cells promotes neuroprotection of retinal ganglion cells in optic nerve crush model.BMC ophthalmology · 2025Article
- Amyloid β-Induced Inflammarafts in Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Glial-mediated immune modulation in glaucomatous neurodegeneration: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Glaucoma is a multifactorial neurodegenerative disease characterized by a progressive optic neuropathy resulting in visual field defects. Elevated intraocular pressure (IOP) is the greatest risk factor for the development of glaucoma, and IOP reduction therapy is the only treatment currently available. However, there are many cases in which retinal degeneration progresses despite sufficient control of IOP. Therefore, it is important to elucidate the pathophysiology of glaucoma that is resistant to current IOP lowering therapies. Experiments using animal glaucoma models show the relationships between microglial neuroinflammatory responses and damage of retinal ganglion cells (RGCs). Inhibition of neuroinflammatory pathways associated with microglial activation appears to be neuroprotective, indicating that microglia may be an important therapeutic target for RGC protection. In this review, we will focus on microglia-induced neuroinflammation in the pathogenesis of glaucoma to offer new insights into the possibility of developing novel neuroprotective therapies targeting microglia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.